Search results for "Stem cell transplantation"

showing 10 items of 452 documents

Emerging Therapeutic Strategies for Traumatic Spinal Cord Injury

2020

Spinal cord injury (SCI) is a debilitating neurologic condition with tremendous socioeconomic impact on affected individuals and the health care system. The treatment of SCI principally includes surgical treatment and marginal pharmacologic and rehabilitation therapies targeting secondary events with minor clinical improvements. This unsuccessful result mainly reflects the complexity of SCI pathophysiology and the diverse biochemical and physiologic changes that occur in the injured spinal cord. Once the nervous system is injured, cascades of cellular and molecular events are triggered at varying times. Although the cascade of tissue reactions and cell injury develops over a period of days …

Nervous systemmedicine.medical_specialtyCordmedicine.medical_treatmentSpinal cord injuryRegenerative MedicineMesenchymal Stem Cell TransplantationNeuroprotection03 medical and health sciences0302 clinical medicineNeural Stem CellsGlyburideGranulocyte Colony-Stimulating FactormedicineHumansHypoglycemic AgentsIntensive care medicineErythropoietinSpinal cord injurySpinal Cord InjuriesNeuronal PlasticityRehabilitationCombination treatmentsHepatocyte Growth Factorbusiness.industryNeurological RehabilitationDecompression SurgicalSpinal cordmedicine.diseaseNeuroregenerationNeuroprotectionClinical trialFibroblast Growth FactorsClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisIntercellular Signaling Peptides and ProteinsSurgeryNeuroregenerationSchwann CellsNeurology (clinical)business030217 neurology & neurosurgeryStem Cell TransplantationWorld Neurosurgery
researchProduct

Investigating the use of primary adult subventricular zone neural precursor cells for neuronal replacement therapies

2002

With the relatively recent discovery that neurogenesis persists throughout life in restricted regions of the adult mammalian brain, including those of human beings, there has been great interest in the use of adult-derived neural stem cells for neuronal replacement. There are many great hurdles that must be overcome in order for such replacement strategies to succeed. In this review, we outline some of these hurdles and discuss recent experiments that investigate the potential of using neural precursor cells found in the subventricular zone of the adult brain for brain repair.

NeuronsStem CellsGeneral NeuroscienceGraft SurvivalNeurogenesisCentral nervous systemBrainSubventricular zoneCell DifferentiationNeurodegenerative DiseasesBiologyMammalian brainNeural stem cellBrain repairTransplantationmedicine.anatomical_structureCell MovementLateral VentriclesPrecursor cellmedicineAnimalsHumansBrain Tissue TransplantationNeuroscienceStem Cell TransplantationBrain Research Bulletin
researchProduct

Transplanting the genetic susceptibility to Crohn’s disease

2003

Susceptibility to Crohn’s disease may be transferred via haematopoietic stem cells, highlighting the pivotal role of genetic factors in the pathogenesis of Crohn’s disease Crohn’s disease (CD) is one of the two most common forms of inflammatory bowel disease (IBD). The prevalence of CD has increased in Western countries over the past decades and mainly young patients are affected, with a peak incidence between 15 and 35 years.1 The aetiology of IBD is still unclear and should be considered as multifactorial according to recent studies.2 Genetic factors seem to play a pathogenic role as well as environmental, infectious, and immunological factors. All of these different aetiological aspects …

Nod2 Signaling Adaptor ProteinCase ReportBiologyInflammatory bowel diseaseProinflammatory cytokinePathogenesisImmune systemCrohn DiseasemedicineGenetic predispositionHumansGenetic Predisposition to DiseaseCrohn's diseasePolymorphism GeneticGastroenterologyIntracellular Signaling Peptides and ProteinsT helper cellT-Lymphocytes Helper-Inducermedicine.diseaseHodgkin Diseasedigestive system diseasesmedicine.anatomical_structureImmunologyCommentaryStem cell5' Untranslated RegionsCarrier ProteinsStem Cell Transplantation
researchProduct

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

2012

Abstract Abstract 785 Background: FLT3 internal tandem duplications (FLT3-ITD) occur in about 25% of acute myeloid leukemia (AML), are associated with cooperating gene mutations (NPM1, DNMT3A), and confer an adverse prognosis. Several studies have indicated that the unfavorable impact of FLT3-ITD is influenced by a number of factors, such as the mutant to wild-type ratio (allelic ratio), insertion site of FLT3-ITD in the beta1 sheet of the tyrosine kinase domain 1, and the molecular background of cooperating mutations. Aims: To evaluate the relative impact of FLT3-ITD allelic ratio and insertion site, as well as cooperating genetic lesions on prognosis and treatment decision making in a lar…

OncologyAcute promyelocytic leukemiaFLT3 Internal Tandem Duplicationmedicine.medical_specialtyNPM1business.industrymedicine.medical_treatmentImmunologyMyeloid leukemiaCell BiologyHematologyHematopoietic stem cell transplantationGene mutationmedicine.diseaseBiochemistrySurgeryQuartilehemic and lymphatic diseasesInternal medicinemedicinebusinesspsychological phenomena and processesNeoadjuvant therapyBlood
researchProduct

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

2010

Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhances the success of the CD34+ cell harvest, even in cases where prior mobilization attempts have failed. Six germ cell tumor patients provided informed consent and were included in the compassionate use program. All patients were heavily pretreated, with a median of 3.5 prior lines of therapy. All failed prior mobilization with G-CSF in combination with chemotherapy. Five patien…

OncologyAdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesPlatelet Engraftmentmedicine.medical_treatmentCD34Hematopoietic stem cell transplantationCyclamsYoung AdultTesticular NeoplasmsHeterocyclic CompoundsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansUltrasonographyTransplantationChemotherapyMobilizationbusiness.industryPlerixaforHematopoietic Stem Cell TransplantationHematologyMiddle AgedNeoplasms Germ Cell and EmbryonalCombined Modality TherapyHematopoietic Stem Cell MobilizationSurgerySeminomamedicine.anatomical_structureStem cellbusinessGerm cellmedicine.drugBone marrow transplantation
researchProduct

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

2017

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationOutcome (game theory)03 medical and health sciencesYoung Adult0302 clinical medicineText miningRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultLetter to the EditorAgedAged 80 and overSalvage Therapybusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle Agedmedicine.diseasePrognosisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemalebusiness030215 immunologyLeukemia
researchProduct

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy i…

2002

The purpose of this study was to evaluate feasibility and efficacy of Rituximab included into a sequential salvage protocol for CD20(+) B-NHL in relapse or induction failure. Twenty-seven patients with CD20(+) B-NHL in relapse or induction failure received Rituximab combined with DexaBEAM (R-DexaBEAM) for stem cell mobilization. Additional ex vivo selection of CD34-positive cells was performed using the CliniMacs device. Two doses of Rituximab were included in the high-dose therapy regimen (HDT). R-DexaBEAM was well tolerated and 26 of 27 patients mobilized sufficient numbers of CD34(+) blood stem cells. Application of R-DexaBEAM resulted in significant depletion of peripheral B cells. No t…

OncologyAdultMalemedicine.medical_specialtyLymphoma B-CellSalvage therapyAggressive lymphomaAntigens CD34Transplantation AutologousDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesCD20Salvage TherapyTransplantationPeripheral Blood Stem Cell Transplantationbiologybusiness.industryBone Marrow PurgingRemission InductionAntibodies MonoclonalHematologyMiddle AgedNeoplastic Cells CirculatingHematopoietic Stem Cell MobilizationSurgeryHematopoiesisTransplantationRegimenImmune Systembiology.proteinRituximabFemaleVirus ActivationStem cellbusinessRituximabmedicine.drugBone marrow transplantation
researchProduct

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable resi…

2020

In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81 center dot 5% an…

OncologyAdultMalemedicine.medical_specialtyNPM1Neoplasm ResidualAdolescentDiseasestem cell transplantationDisease-Free Survival03 medical and health sciencesEuropean LeukemiaNet0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineHumansacute myeloid leukaemiamolecular analysisCumulative incidenceAgedbusiness.industryInduction chemotherapyMyeloid leukemiaNuclear ProteinsHematologyInduction ChemotherapyMiddle AgedNeoplasm ProteinsTransplantationEuropeSurvival RateHaematopoiesisLeukemia Myeloid Acute030220 oncology & carcinogenesisleukaemiaMutationFemalebusinessNucleophosmin030215 immunologyBritish journal of haematologyReferences
researchProduct

A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.

2013

Thymidine phosphorylase (TYMP), an enzyme involved in nucleotide synthesis, has been implicated in critical biological processes such as DNA replication, protection against mutations, and tissue repair. In this work, we retrospectively evaluated the influence of a polymorphism in the TYMP gene (rs112723255; G/A) upon the outcome of 448 patients subjected to allogeneic stem cell transplantation (allo-SCT) from an human leukocyte antigen (HLA)-identical sibling donor. The TYMP genotype of patients correlated with overall survival—carriers of the minor allele (A) being at an increased risk of dying after transplantation (hazard ratio, HR = 1.9; P = 0.004). This effect was mostly due to differe…

OncologyAdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeGraft vs Host DiseaseHuman leukocyte antigenDiseaseBiologyRisk FactorsInternal medicineGenotypemedicineHumansTransplantation HomologousAlleleChildAllelesAgedRetrospective StudiesThymidine PhosphorylasePolymorphism GeneticHistocompatibility TestingSiblingsHazard ratioInfantHematologyMiddle AgedMinor allele frequencyTransplantationSurvival RateChild PreschoolHematologic NeoplasmsImmunologyChronic DiseaseFemaleComplicationStem Cell TransplantationAmerican journal of hematology
researchProduct

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in…

2017

Background The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to wh…

OncologyAdultMalemedicine.medical_specialtyautologous stem cell transplantationAdolescentLymphomaMedizinprimary CNS lymphoma whole brain radiotherapy autologous stem cell transplantationPhases of clinical researchThioTEPATransplantation AutologousDisease-Free SurvivalCentral Nervous System Neoplasms03 medical and health sciencesYoung Adult0302 clinical medicineAutologous stem-cell transplantationprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal ArticleMedicineHumansAgedManchester Cancer Research CentreDose-Response Relationship Drugbusiness.industryResearchInstitutes_Networks_Beacons/mcrcInduction chemotherapyBrainHematologyMiddle AgedCombined Modality Therapy3. Good healthSurgeryTransplantationRegimenMethotrexate030220 oncology & carcinogenesiswhole brain radiotherapyRituximabFemalebusiness030215 immunologymedicine.drugStem Cell Transplantation
researchProduct